Zinbryta Approval History
Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).
In March 2018, Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta for the treatment of relapsing multiple sclerosis.
Development History and FDA Approval Process for Zinbryta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.